+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 63 Pages
  • August 2024
  • GlobalData
  • Cipla Inc
  • ID: 4372867
Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cipla Ltd (Cipla) manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products in therapeutic areas such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices and conducts research and development to develop new medicines and drug delivery systems. The company has operations in India, the US, Canada and South Africa among others. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd Key Recent Developments

  • Aug 20, 2024: Cipla : Retirement of Mr. S. Radhakrishnan as Non-Executive Director of the Company
  • Jul 26, 2024: Cipla Receives Form 483 for its dose Manufacturing Facility in Goa, India
  • Jun 28, 2024: Cipla Announces Dissolution of wholly owned step-down subsidiary in South Africa
  • May 10, 2024: Cipla : Outcome Of Board Meeting Held On 10th May 2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Cipla Ltd - Key Facts
  • Cipla Ltd - Key Employees
  • Cipla Ltd - Key Employee Biographies
  • Cipla Ltd - Major Products and Services
  • Cipla Ltd - History
  • Cipla Ltd - Company Statement
  • Cipla Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Cipla Ltd - Business Description
  • Business Segment: New Ventures
  • Overview
  • Performance
  • Business Segment: Pharmaceuticals
  • Overview
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: South Africa
  • Performance
  • Geographical Segment: United States of America
  • Performance
  • R&D Overview
  • Cipla Ltd - Corporate Strategy
  • Cipla Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Cipla Ltd - Strengths
  • Cipla Ltd - Weaknesses
  • Cipla Ltd - Opportunities
  • Cipla Ltd - Threats
  • Cipla Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Cipla Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 20, 2024: Cipla : Retirement of Mr. S. Radhakrishnan as Non-Executive Director of the Company
  • Jul 26, 2024: Cipla Receives Form 483 for its dose Manufacturing Facility in Goa, India
  • Jun 28, 2024: Cipla Announces Dissolution of wholly owned step-down subsidiary in South Africa
  • May 10, 2024: Cipla : Outcome Of Board Meeting Held On 10th May 2024
  • May 08, 2024: Cipla Limited : USFDA Inspection at Company’s Manufacturing Facility in Kurkumbh, Maharashtra, India
  • May 08, 2024: USFDA Inspection At Company’s Manufacturing Facility In Kurkumbh, Maharashtra, India
  • Apr 10, 2024: Cipla Receives Form 483 for its dose Manufacturing Facility in Raigad, India
  • Mar 26, 2024: Sanofi & Cipla Announce Exclusive Distribution Partnership to Expand Reach of CNS Portfolio in India
  • Mar 26, 2024: Cipla : Mr. Rajeev Kumar Sinha Appointed as Senior Management Personnel and Global Chief Manufacturing Officer
  • Mar 15, 2024: Cipla Announces Appointment of Senior Management
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Cipla Ltd, Key Facts
  • Cipla Ltd, Key Employees
  • Cipla Ltd, Key Employee Biographies
  • Cipla Ltd, Major Products and Services
  • Cipla Ltd, History
  • Cipla Ltd, Other Locations
  • Cipla Ltd, Subsidiaries
  • Cipla Ltd, Affiliate
  • Cipla Ltd, Joint Venture
  • Cipla Ltd, Key Competitors
  • Cipla Ltd, Ratios based on current share price
  • Cipla Ltd, Annual Ratios
  • Cipla Ltd, Interim Ratios
  • Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Cipla Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Cipla Ltd, Performance Chart (2020 - 2024)
  • Cipla Ltd, Ratio Charts
  • Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sun Pharmaceutical Industries Ltd
  • Piramal Enterprises Ltd
  • Dr. Reddy's Laboratories Ltd
  • Zydus Lifesciences Ltd
  • Aurobindo Pharma Ltd
  • Torrent Pharmaceuticals Ltd
  • Lupin Ltd
  • Biocon Ltd